Searchable abstracts of presentations at key conferences in endocrinology

ea0010p42 | Endocrine tumours and neoplasia | SFE2005

Octreotide in the treatment of pthrp related hypercalcaemia in neuroendocrine tumours: a case report and literature review

Jones R , OaGrady J , Chambers S , Heaton N , Ramage J , Aylwin S

Intro: A subset of pancreatic and gastric neuroendocrine tumours (NET) are associated with hypercalcaemia attributed to tumour secretion of parathyroid hormone related peptide (PTHrP). Hypercalcaemia may be severe and refractory to conventional treatment....

ea0096p25 | Section | UKINETS2023

Sequencing of treatment in G1-2 pancreatic neuroendocrine tumour - a case study

J Shi , D Sarker , J Mencel , R Srirajaskanathan , S Brown , D Clement , J Ramage , S Dolly

Herein, we present the case of a 48yo Caucasian male diagnosed with a well differentiated (WD) pancreatic NET. At primary resection in 2014 pathological staging was pT3N1M0 R0 with Ki67 4%. 5 years later he developed recurrence in local lymph nodes and started on lanreotide followed by IRE on subsequent progression. In 2020, there was strongly DPET-avid metastases in mesenteric nodes and liver, so he was enrolled onto the COMPETE trial1. There was sequential progressive diseas...

ea0068p13 | Abstracts | UKINETS2019

Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome: a single centre study from a centre of excellence

Davis LM , Nicou N , Martin W , Corcoran B , Mulholland N , Srirajaskanthan R , Ramage J , Wendler O , Vivian G

Introduction: Perioperative mortality of patients who undergo heart valve surgery for carcinoid heart valve disease (CHVD) has been observed to be high (5–10%). We investigated whether peptide receptor radiotherapy (PRRT) with Lutetium-177 Dotatate can be used safely in patients with neuroendocrine neoplasms (NEN) and CHVD and if there is an associated survival advantage by reducing overall exposure of the valves to high doses of vasoactive peptides.<p class="abstext"...